32 million people in the US experience loss of bone mineral density (osteoporosis) while aging, with elevated risk of fracture. There are over 400,000 cases of femur fractures in the US every year. Studies show that roughly 10% of those femur fracture patients will experience contralateral fracture within two to five years. Patients who sustain a contralateral fracture undergo a more costly operation, have reduced mobility and statistically have a higher mortality rate.
Simfini-OSTEO will identify which patients are at high risk of contralateral hip fracture – enabling better planning, treatment and oversight to minimize the risk.
Diabetes patients are at higher risk of hip fracture. While patients with diabetes type II have twice the risk of a normal person to fracture the hip, diabetes type I have six times the risk to fracture. There is no marker or diagnostic test to show that they are at risk and DXA (dual-energy x-ray absorptiometry) has false results, with normal to high bone density readings, which are not correlated to actual fractures. Furthermore, there are no monitoring tools to assess drug treatment effectiveness, or other treatment given to the patient that, according to their doctor, are at a higher risk to fracture.
Simfini-Diabetes will identify which patients are at high risk of contralateral hip fracture – enabling better planning, treatment and oversight to minimize the risk.
Simfini-TUMOR offers accurate assessment of the strength of bone affected by primary or metastatic tumors to determine the likelihood of fracture enabling the MD to decide if the patient requires prophylactic surgery or if non-surgical treatments are sufficient for the patient. There are more than 90,000 cases of metastasized cancer in the femur annually.
By accurately determining whether or not the tumor has weakened the patient's bone to the point that a pathologic fracture is imminent, physicians benefit from a assessment of the necessity of prophylactic surgery. Simfini-TUMOR offers a highly reliable prediction model and methodology reducing the number of unnecessary surgeries with the related cost, rehabilitation and complications while at the same time ensuring that those that at high risk of a pathologic fracture are operated on prophylactically.
About 15% of nearly 400,000 total hip replacement (THR) procedures performed in the US annually are revisions, causing additional patient suffering and hospital expenses (in 2012, the total average cost for THR surgery in the US was $40,000). A meaningful percentage of these revision surgeries are due to improper selection of hip implants.
Simfini-IMPLANT helps select the optimal femur implant in THR by analyzing the bone-implant structure while taking into account all parameters, such as reduction in bone density due to stress shielding. The novel platform enables the surgeon to select the implant that is the most biomechanically appropriate for the specific patient from the available implants at the specific hospital. As a result, surgical outcome and patient satisfaction are improved, while hospital expenses are reduced.